S-Adenosyl-L-methionine (SAMe) is a naturally occurring molecule distributed to virtually all body tissues and fluids. It is of fundamental importance in a number of biochemical reactions involving enzymatic transmethylation, contributing to the synthesis, activation and/or metabolism of such compounds as hormones, neurotransmitters, nucleic acids, proteins, phospholipids and certain drugs. The administration of a stable salt of SAMe, either orally or parenterally, has been shown to restore normal hepatic function in the presence of various chronic liver diseases (including alcoholic and non-alcoholic cirrhosis, oestrogen-induced and other forms of cholestasis), to prevent or reverse hepatotoxicity due to several drugs and chemicals such as alcohol, paracetamol (acetaminophen), steroids and lead, and to have antidepressant properties. In all of these studies SAMe has been very well tolerated, a finding of great potential benefit given the well-known adverse effects of tricyclic antidepressants with which it has been compared in a few trials.
Thus, with its novel mechanisms of action and good tolerability, SAMe is an interesting new therapeutic agent in several diverse disease conditions, but its relative value remains to be determined in appropriate comparisons with other treatment modalities in current use.
Role of S-Adenosyl-L-Methionine in Cell Biochemistry
S-Adenosyl-L-methionine (commonly known as SAMe) acts as a methyl group donor in many transmethylation reactions, including those involved with the biosynthesis of phospholipids which play several important roles within the cell membrane. These roles include regulation of cellular enzymatic and bioelectrical activity and the maintenance of membrane fluidity. Loss of the latter in brain cells of aged animals has been linked with loss of dopaminergic and β-adrenergic binding sites and changes in cell membrane composition. The exogenous administration of SAMe maintains normal phospholipid ratios and restores enzymatic activity leading to normalisation of metabolic processes within the cell. This may explain, at least in part, the effect of SAMe in normalising several indices of hepatic function which are altered in chronic liver disease where changes in cell membrane composition and enzymatic activity of hepatocytes have been demonstrated. Activation of enzymes which affect the synthesis and metabolism of neurotransmitters may also be related to maintenance of normal cell membrane function and may explain the effects of SAMe on mood in patients with affective disorders.
Release of methyl groups from the SAMe molecule results in activation of the transsulphuration pathway leading to the formation of glutathione, the main cellular antioxidant responsible for the detoxification of various compounds, including lead and paracetamol. Thus, regulation of the transsulphuration pathway is an important effect and one which may be responsible for its beneficial action on drug-and chemical-induced liver disease.
The almost universal distribution of SAMe in body tissues and its complex role in metabolic processes, all of which depend in some way on methylation reactions, complicate the complete characterisation of its effects on cellular biochemistry. As a result the mechanism of its actions in various diverse disease states remains speculative.
Pharmacodynamic Properties of Exogenous SAMe
The role of SAMe in transmethylation reactions and as a precursor of sulphur-containing compounds via the transsulphuration pathway is fundamentally important in the liver, as both pathways have been shown to be abnormal in the presence of liver disease. In the presence of cirrhosis, methionine metabolism is decreased, and the activities of S-adenosyl-methionine synthetase and phospholipid methyltransferase are reduced, possibly leading to lessened production of sulphated compounds and phosphatidylcholine. Levels of the important thiol compounds glutathione and cysteine are reduced in plasma.
Various animal models have been used to demonstrate the protective effect of SAMe against intrahepatic cholestasis induced by a range of compounds, including oestrogen. The mechanism of action of SAMe in oestrogen-induced cholestasis appears to be via increased enzyme activity and fluidity of liver plasma membranes, and maintenance of phospholipid activity in bile salt transport systems. Preliminary findings of a preventative effect of SAMe in women with oestrogen-induced cholestasis have been augmented by results of small therapeutic trials (see below).
Acute toxicity studies in animals reveal that SAMe can prevent mortality induced by paracetamol (acetaminophen) and acute and chronic lead poisoning. Some success has been achieved with the use of SAMe in treating patients with lead poisoning (see below). Maintenance of glutathione stores is instrumental in the prevention by SAMe of hepatotoxicity due to these agents.
SAMe administered to rats and baboons subjected to chronic ethanol ingestion has been shown to maintain or prevent depletion of glutathione levels, to normalise mitochondrial enzyme activity, and to prevent production of acetaldehyde and deposition of fat in the liver. In healthy volunteers, plasma concentrations of ethanol and acetaldehyde were significantly lower when SAMe was ingested concomitantly with ethanol.
SAMe has been shown in animals and humans to be distributed to the brain where it stimulates the activity of dopaminergic and serotonergic pathways, probably through its involvement in transmethylation processes. Levels of SAMe, and of 5-hydroxy indoleacetic acid (5HIAA) and homovanillic acid, increase in the cerebrospinal fluid of humans after administration of SAMe. The interplay of folate and SAMe pathways in influencing mood is a topic of considerable study, with recent work linking red cell folate levels to levels of 5HIAA in cerebrospinal fluid. Reductions in S-adenosyl-methionine syntlietase and phosphatidylcholine in erythrocytes of depressed patients suggest a disruption of SAMe-dependent pathways, and form the basis for the use of SAMe in depressed patients (see below).
SAMe has been shown invitroto enhance ATP levels in erythrocytes, enabling restoration of cell shape and conservation of deformability. Invivo, blood viscosity was reduced following injection of SAMe.
Limited trials in healthy volunteers have demonstrated very low bioavailability after oral administration of SAMe, indicative of a significant first-pass effect and rapid metabolism in the liver. Peak plasma concentrations obtained with an enteric-coated tablet formulation are dose related, with a peak plasma concentration of 0.5 to 1 mg/L achieved 3 to 5 hours after single doses in the range of 400 to 1000mg.
Single intravenous doses of SAMe (100 and 500mg) have yielded volumes of distribution of 0.41 and 0.44 L/kg, respectively. Plasma protein binding is 5% or less. The rate of distribution to all body tissues is related to their degree of vascularity and blood flow. SAMe crosses the blood-brain barrier, with slow accumulation in the cerebrospinal fluid. Animal data suggest that exogenously administered SAMe follows the same metabolic pathways as the endogenous compound, namely, transmethylation, transsulphuration and decarboxylation. By 24 hours after intravenous administration of SAMe 100 or 500mg in healthy volunteers, 34% and 40% of unchanged drug, respectively, had appeared in urine. Urinary excretion of an oral 200mg dose of SAMe has been reported as 15.5% in 48 hours with faeces containing 23.5% at 72 hours. The remainder was probably incorporated into stable cellular pools. The half-life of SAMe in healthy volunteers was 80 to 100 minutes and 121 ininutes in a small group of patients with chronic liver disease.
Use in Patients with Liver Dysfunction
Trials in small numbers of patients with various types of chronic liver disease, including biliary or alcoholic cirrhosis, hepatitis or drug-induced cholestasis, have confirmed the short term effect of SAMe (intravenously or orally) relative to placebo in normalising measures of liver function (e.g. plasma levels of aspartate aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, cysteine, taurine and methionine). Patients with chronic lead poisoning have shown reversal of liver enzyme abnormalities after SAMe therapy. Moreover, severe pruritus has been ameliorated in patients with cholestasis of diverse aetiology.
Of interest is the apparent ability of SAMe, when given concomitantly, to protect against hepatic dysfunction caused by other drugs, including steroids, certain anticon-vulsants, and tricyclic antidepressants, paracetamol and alcohol. SAMe was effective in normalising biochemical parameters in small groups of patients with metabolic disorders of bilirubin and porphyrin metabolism, such as Gilbert’s syndrome and infantile porphyria cutanea tarda.
Use in Patients with Affective Disorders
The major effect of SAMe in depressed patients is elevation of mood, the precise mechanism of which is unknown. Non-comparative trials in small groups of patients with various types of depression have shown a consistent improvement in mood with SAMe in daily dosages up to 1600mg orally or 500mg parenterally for up to 6 weeks, as determined by the Hamilton rating scale, with those patients recently diagnosed or previously responding to antidepressants being most improved. In a number of short term randomised, double-blind trials SAMe 75 to 400mg administered parenterally was consistently superior to placebo and was at least as effective as other antidepressant drugs administered parenterally (nomifensine, amitriptyline, imipramine and clomipramine), generally having an onset of action within the first 2 weeks of treatment. Furthermore, in combination with another agent (the β2-agonist fenoterol, mianserin or clomipramine), SAMe shortened the latency period and improved the response as compared with the other drug alone. The use of SAMe as an adjunct to treatment with other antidepressants is worthy of study if the time to treatment response can be reduced, especially in suicidal patients. Furthermore SAMe treatment was well tolerated, an asset in patients who experience significant adverse effects from tricyclic antidepressant therapy. The relative efficacy of SAMe administered orally should be pursued in longer term trials.
Use in Other Disorders
The wide range of effects of SAMe administration has led to the investigation of its use in many diverse conditions. Isolated reports have included clinical trials involving patients with Alzheimer’s; disease and epilepsy, where its effect was predominantly on mood but no change in the underlying condition could be demonstrated; migraine, where the incidence and severity of attacks was reduced; and primary fibromyalgia, where both joint pain and associated depression were improved. However, none of the above effects of SAMe have been adequately studied in well-designed trials s’uch that any conclusions can be drawn regarding its possible efficacy.
SAMe is very well tolerated. At oral doses of up to 1600mg daily no adverse effects have been noted other than occasional mild gastrointestinal effects. In a study of 20,641 patients with osteoarthritis the tolerability was assessed as good to very good in 87% of patients, the withdrawal rate being 5.2%, primarily early in treatment when doses were highest. In depressed patients tolerability was also good, with only a few patients developing anxiety. However, the transition from depression to hypomania was noted in some patients with bipolar illness.
The recommended daily dose of SAMe for the treatment of liver disorders, such as cholestasis, is 800mg parenterally or 1600mg orally. For parenteral administration in depressive illness 200 to 400 mg/day should be given for 15 to 20 days. Oral therapy is in the dose range 400 to 1600 mg/day.
KeywordsTaurine Chronic Liver Disease Cholestasis Clomipramine Lead Poisoning
Unable to display preview. Download preview PDF.
- Adachi Y, Nanno T, Kanbe A, Inufusa H, Yamashita M, et al. The effects of S-adenosylmethionine on intrahepatic cholestasis. Japanese Archives of Internal Medicine 33: 185–192, 1986Google Scholar
- Agnoli A, Martucci N, Manna V. On the antidepressant effect of SAMe: clinical and pharmaco-EEG study with SAMe alone and in association with a beta-2 stimulant drug, phenoterole. Clinical Neuropharmacology 7 (Suppl. 1): 104–105, 1984Google Scholar
- Altomare E, Vendemiale G, Marchesini G, Le Grazie C, Di Padova C. Increased bioavailability of sulfurated compounds after S-adenosylmethionine (SAMe) administration to alcoholics. In Kuriyama et al. (Eds) Biomedical and social aspects of alcohol and alcoholism, pp. 353–356, Elsevier Science Publishers B.V., 1988Google Scholar
- Alvarez E. SAMe and depression. In Mato (Ed.) 1st Conference on biomedical pharmacological and clinical aspects of transmethylation, pp. 107–114, Spain, 1986Google Scholar
- Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAM and other antidepressant drugs. Cell Biology Reviews S1: 103–110, 1987Google Scholar
- Andreoli V, Campedelli A, Maffei F. La S-adenosil-L-metionina (SAMe) in geropsichiatria: uno studio clinico controllato « in a perto » nelle sindromi depressive dell’eta senile. Giornale di Gerontologia 25: 172–180, 1977Google Scholar
- Arias IM. Ion transport into and out of the liver. In Keppler D, Popper H, Bianchi L, et al. (Eds) Mechanisms of hepatocyte injury and death, pp 49–56, MTP Press, Lancaster, UK, 1983Google Scholar
- Arias IM. Mechanisms and consequences of ion transport in the liver. In Popper H, Schaffner F (Eds) Progress in liver diseases, vol. III, pp. 145–159, Grune & Stratton Inc, Orlando, USA, 1986Google Scholar
- Artale F, Francisci A, Espureo M, Sergio G, Cramarossa L, et al. Effects of S-adenosyl-L-methionine on hemorheological changes induced by exercise in patients with peripheral occlusive arterial diseases. Current Therapeutic Research 32: 520–528, 1982Google Scholar
- Barber JR, Morimoto BH, Brunauer LS, Clarke S. Metabolism of S-adenosyl-L-methionine in intact human erythrocytes. Biochimica et Biophysica Acta 887: 361–372, 1986Google Scholar
- Batlle AM Del C, Paredes SR, Fukuda H, Kozicki PA, Rossetti MV. S-adenosyl-L-methionine, a mechanism for its action on lead mobilisation and disposal in lead poisoning. Biochemical Archives 2: 293–303, 1986Google Scholar
- Batlle AM Del C, Stella AM, De Kaminsky AR, Kaminsky C, Mariano HG. Two cases of infantile porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral chloroquine. British Journal of Dermatology 116: 407–415, 1987Google Scholar
- Bombardieri G, Milani A, Bernardi L, Rossi L. Effects of S-ad-enosyl-methionine (SAMe) in the treatment of Gilbert’s syndrome. Current Therapeutic Research 37: 580–585, 1985Google Scholar
- Bombardieri G, Pappalardo G, Bernardi L, Barra D, Di Palma A, et al. Intestinal absorption of S-adenosyl-L-methionine in humans. International Journal of Clinical Pharmacology, Therapy and Toxicology 21: 186–188, 1983Google Scholar
- Cabrero C, Martin Duce A, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 88: 1530–1534, 1988Google Scholar
- Cacciatore L, Cozzolino G, Varriale A, Dionisio M. Treatment of pruritus in chronic liver disease with S-adenosylmethionine. European Journal of Clinical Investigation 19 (Part II): A15, 1989Google Scholar
- Caruso I, Fumagalli M, Boccassini L, Sarzi Puttini P, Santandrea S, et al. Treatment of depression in rheumatoid arthritic patients: a comparison of S-adenosylmethionine (Samyr®) and placebo in a double-blind study. Clinical Trials Journal 24: 305–310, 1987Google Scholar
- Celani T, Iorio G, Vacca L, Amati A, Del Vecchio M. Electroen-cephalographic control with frequency analysis in depressed patients treated with SAMe. Current Therapeutic Research 23: 525–527, 1978Google Scholar
- Cibin M, Gentile N, Ferri M, Canton G, Gallimberti L. S-adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In Kuriyama et al. (Eds) Biomedical and social aspects of alcohol and alcoholism, pp. 357–360, Elsevier Science Publishers B.V., 1988Google Scholar
- De Leo D. S-adenosyl-L-methionine (SAMe) in clinical practice: preliminary report on 75 minor depressives. Current Therapeutic Research 37: 658–661, 1985Google Scholar
- De Leo D. S-adenosylmethionine as an antidepressant: a double-blind trial versus placebo. Current Therapeutic Research 41: 865–870,1987Google Scholar
- Di Padova C, Tritapepe R, Di Padova F, Frezza M, Stramentinoli G. S-adenosyl-L-methionine antagonizes oral contraceptive-induced bile cholesterol supersaturation in healthy women: preliminary report of a controlled randomized trial. American Journal of Gastroenterology 79: 941–944, 1984aPubMedGoogle Scholar
- Di Padova C, Tritapepe R, Rovagnati P, Pozzoli M, Stramentinoli G. Decreased blood levels of ethanol and acetaldehyde by S-adenosyl-L-methionine in humans. Archives of Toxicology (Suppl. 7): 240–242, 1984bGoogle Scholar
- Di Padova C, Vendemiale G, Marchesini G. Increased bioavailability of sulfurated compounds after S-adenosylmethionine (SAMe) administration in alcoholics. Fourth Congress of the International Society for Biomedical Research on Alcoholism, Kyoto, 26 June–2 July, 1988 p. 476, 1988Google Scholar
- Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R, et al. Therapy of schizophrenia and depressive disorders with S-adenosyl-L-methionine. IRCS (Research on: Clinical Pharmacology and Therapeutics; Human Metabolism and Nutrition; Psychiatry and Clinical Psychology; Psychology) 2: 1015, 1974Google Scholar
- Fiaccadori F, Frezza M, Di Padova C. Oral S-adenosylmethionine (SAMe) therapy in cholestatic patients with chronic liver disease. Interim analysis of a placebo (P) controlled clinical trial. Journal of Hepatology 7 (Suppl. 1): 31, 1988Google Scholar
- Finkelstein JD, Kyle WE, Martin JJ, Pick A-M. Activation of cystathionine synthase by adenosylmethionine and adenosy-lethionine. Biochemical and Research Communications 66: 81–87, 1975Google Scholar
- Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-gastroenterology, in press, 1989Google Scholar
- Frezza M, Di Padova C. Italian Study Group for SAMe in Liver Disease. Multicenter placebo controlled clinical trial of intravenous and oral S-adenosylmethionine (SAMe) in cholestatic patients with liver disease. Abstract no. 330. Hepatology 7: 1105, 1987aGoogle Scholar
- Frezza M, Pozzato G, Pison G, Zalateo C, Chiesa L, et al. S-adenosylmethionine counteracts oral contraceptive hepatotoxicity in women. American Journal of Medical Sciences 293: 234–238, 1987bGoogle Scholar
- Fricker G, Landmann L, Meier PJ. Ethinylestradiol (EE) induced structural and functional alterations of rat liver plasma membranes and their reversal by S-adenosylmethionine (SAMe) in vitro. Abstract no. 24. Hepatology 8: 1224, 1988Google Scholar
- Gentile S, Persico M, Russo FS, Le Grazie C, Di Padova C, et al. Effect of S-adenosylmethionine (SAMe) on antipyrine and rifamycin-SV half-life and serum total bibirubin in cirrhotic patients. Journal of Hepatology, in press, 1989Google Scholar
- Giannuoli G, Tine F, Malizia G, Saracco G, Verme G, et al. S-adenosylmethionine for treatment of pruritus in compensated chronic liver disease. A pilot study. Abstract no. 24. Hepatology 6: 1110, 1986Google Scholar
- Hirata F, Viveros OH, Diliberto EJ, Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proceedings of the National Academy of Sciences 78: 1718–1721, 1978Google Scholar
- Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH. Oral S-adenosyl-methionine in depression: a double-blind, placebo controlled trial. Submitted to American Journal of Psychiatry for publication Küfferle B, Grünberger J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. In Costa & Racagni (Eds) Typical and atypical antidepressants: Clinical Practice, pp. 175–180, Raven Press, New York, 1982Google Scholar
- Lafuenti G, Plotti G, Nicolanti G, Caruso A, Tibollo FG, et al. Valutazione delie modificazioni di parametri clinici e biochimici in gravide con colestasi in terapia con S-adenosyl-L-methionine per os. Giornale Italiano di Ostetricia e Ginecologia 5: 357–361, 1988Google Scholar
- Lieber CS, DeCarli IM, Kim C, Lowe N, Sasaki R, et al. S-adenosyl-L-methionine (SAMe) attenuates alcohol-induced mitochondrial injury in the baboon. Abstract no. 773. Hepatology 8: 1412, 1988Google Scholar
- Loguercio C, Nardi G. Abnormal concentration of red blood cell cysteine in cirrhotics and its correction by S-adenosylmethionine. Abstract no. 311. Journal of Hepatology 5 (Suppl. 1): 161, 1987Google Scholar
- Manzillo G, Fiaccadori F, Frezza M, Di Padova C. Results of a placebo (P) controlled clinical trial with oral S-adenosylmethionine (SAMe) in cholestatic patients with chronic liver disease. Abstract no; 187. Hepatology 8: 1265, 1988Google Scholar
- Marchesini G, Almasio P, Luca A, Maggioni Moratti E, Pisi E, et al. Sulfur amino acid (SAA) pattern in compensated chronic liver diseases. European Journal of Clinical Investigation 19 (Part II): A94, 1989Google Scholar
- Marchesini G, Bianchi GP, Lolli R, Zoli M, Pisi E. Effect of S-adenosylmethionine (SAMe) on plasma levels of sulfur-containing amino acids (SCAA) in patients with liver cirrhosis. Journal of Hepatology 7 (Suppl. 1): 148, 1988Google Scholar
- Martin Duce A, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 8: 65–68, 1988Google Scholar
- Mazzanti R, Arcangeli A, Salvadori G, Smorlesi C, Di Perri T, et al. On the anti-steatosic effects of S-adenosyl-L-methionine in various chronic liver diseases (multicentre study). Current Therapeutic Research 25: 25–34, 1979Google Scholar
- Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. In Costa & Racagni (Eds) Typical and atypical antidepressants: clinical practice, pp. 151–156, Raven Press, New York, 1982Google Scholar
- Nanno T, Adachi Y, Takahashi H, Yamashita M, Kobayashi H, et al. Effect of S-adenosyl-L-methionine (SAMe) on experimental intrahepatic cholestasis. Proceedings Japan Society of Clinical Biochemistry and Metabolism 24: 18–19, 1987Google Scholar
- Ortiz P, Martin Duce A, Cabrero C. Phospholipid methylation and S-adenosylmethionine synthesis in human liver cirrhosis. Cell Biology Reviews SI: 59–66, 1987Google Scholar
- Paredes SR, Kozicki PA, Batlle AM Del C. S-adenosyl-L-methionine a counter to lead intoxication? Comparative Biochem-istry and Physiology 82B: 751–757, 1985bGoogle Scholar
- Pezzoli C, Kienle MG, Stramentinoli G. S-adenosylmethionine and glutathione. Submitted to Biochemical Pharmacology for publicationGoogle Scholar
- Piccinino F, Sagnelli E, Pasquale G, Giusti G. S-adenosyl-methionine in patients with chronic active hepatitis treated with steroids. Italian Journal of Gastroenterology 14: 186–188, 1982Google Scholar
- Placidi GF, Fornaro P, Guarneri M, Stramentinoli G. Localization of S-[methyl-14C] adenosyl-L-methionine in pregnant mice and fetuses as determined by autoradiography. European Journal of Drug Metabolism and Pharmacokinetics No. 3: 157–161, 1979Google Scholar
- Placidi GF, Stramentinoli G, Pezzoli C, Cassano GB. Distribution of S-adenosyl-L-(methyl-14C)methionine in animals. Arzneimittel-Forschung/Drug Research 27: 1680–1684, 1977Google Scholar
- Reynolds EH, Carney MWP, Toone BK, Thomas CS, Edeh J, et al. Transmethylation and neuropsychiatry. Cell Biology Reviews S1: 93–102, 1987Google Scholar
- Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS. Oral S-adenosylmethionine in major depression. Abstract no. IOC. Presented at the 141st Annual Meeting of the American Psychiatric Association, Montreal, 7–12 May, 1988aGoogle Scholar
- Salerno MT, Vendemiale G, Amendola A, Trione T, Palasciano G, et al. Effect of orally administered S-adenosyl-L-methionine (SAMe) in patients with alcoholic liver disease. Abstract no. 756. Digestive Diseases and Sciences 31 (Suppl): 192S, 1986Google Scholar
- Salvadorini F, Galeone F, Saba P, Tognetti G, Mariani G. Evaluation of S-adenosylmethionine (SAMe) effectiveness on depression. Current Therapeutic Research 27: 908–918, 1980Google Scholar
- Schreiber AJ, Warren G, Sutherland E, Simon FR. S-adenosylmethionine (SAMe)-induced cytoprotection against bile acid-induced cholestasis. Abstract. Gastroenterology 84: 1395, 1983Google Scholar
- Stramentinoli G. Adomet as a drug: pharmacokinetic and pharmacological aspects. In Borchardt et al. (Eds) Biological methylation and drug design, pp. 315–326, The Humana Press, Clifton, New Jersey, 1986aGoogle Scholar
- Stramentinoli G. Modulation of membrane fluidity by S-adenosylmethionine treatment in different experimental conditions. In Mato (Ed.) 1st Conference on Biochemical Pharmacological and Clinical Aspects of Transmethylation, pp. 97–104, Spain, 1986bGoogle Scholar
- Stramentinoli G. Various pharmacological aspects of S-adenosylmethionine: an overview. Cell Biology Reviews S1: 67–80, 1987aGoogle Scholar
- Torta R, Zanalda E, Rocca P, Ravizza L. Inhibitory activity of S-adenosyl-L-methionine on serum gamma-glutamyl-transpep-tidase increase induced by psychodrugs and anticonvulsants. Current Therapeutic Research 44: 144–159, 1988Google Scholar
- Vendemiale G, Altomare E, Altavilla R, Le Grazie C, Di Padova C, et al. S-adenosylmethionine (SAMe) improves acetaminophen metabolism in cirrhotic patients. Journal of Hepatology, in press, 1989bGoogle Scholar
- Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology, in press, 1989aGoogle Scholar
- Vendemiale G, Altomare E, Trizio T, Salerno MT, Stufano N, et al. Effect of S-adenosyl-L-methionine on hepatic glutathione in patients with liver injury. Abstract 358. Digestive Diseases and Sciences 31 (Suppl.): 92, 1986Google Scholar
- Zeisel SM, Poole JR. Dietary intake of methionine: influence on brain S-adenosylmethionine. In Usdin E, Boechardt RT, Greveling CR (Eds) Transmethylation, pp 59–68, Elsevier/North-Holland, The Netherlands, 1979Google Scholar